Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies
Under an Elsevier user license
open archive
Keywords
Monoclonal antibodies to nerve growth factor
Tanezumab
Fulranumab
Osteonecrosis
Rapidly progressive osteoarthritis
Cited by (0)
- a
Dr Hochberg was a member of the Adjudication Committee for Pfizer Inc., and received compensation for this activity as well as for consulting for Pfizer Inc.
Published by Elsevier Ltd.